Product Information
VIOKACE 20,880-78,300 UNITS TB is a brand product labeled by Aimmune Therapeutics, Inc., priced at $8.2125 per EA under NDC 73562020810. Its NADAC has been published 111 times since Aug 21, 2024.
Strength
78300; 20880; 78300 [USP'U]/1; [USP'U]/1; [USP'U]/1
Manufacturer
Aimmune Therapeutics, Inc.NDC
73562020810
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
12/31/2025
Active Ingredients
PANCRELIPASE AMYLASE; PANCRELIPASE LIPASE; PANCRELIPASE PROTEASEApproval Type
Biologic (BLA)
FDA Application
BLA022542On Market Since
3/1/2021
Price Statistics
The NADAC for VIOKACE 20,880-78,300 UNITS TB has been published 111 times since Aug 21, 2024, and over the history we have for it it has risen 3.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.2125 per EA |
|---|---|
| All-time high | $8.2125 (Sep 30, 2026) |
| All-time low | $7.9288 (Nov 20, 2024) |
| 52-week high | $8.2125 |
| 52-week low | $7.9711 |
| Median price | $7.9772 |
| Average price | $8.0486 |
| Largest weekly change | +3.0% (Jan 7, 2026) |
| Weeks tracked | 111 |
| Tracking since | Aug 21, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Pancrelipase market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aimmune Therapeutics, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Pancrelipase market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VIOKACE 20,880-78,300 UNITS TB?
The current National Average Drug Acquisition Cost (NADAC) for VIOKACE 20,880-78,300 UNITS TB, manufactured by Aimmune Therapeutics, Inc., is $8.2125 per EA (NDC 73562020810), effective Sep 30, 2026.
How has the price of VIOKACE 20,880-78,300 UNITS TB changed over time?
Over the history we have for it, the NADAC for VIOKACE 20,880-78,300 UNITS TB has risen 3.4%. It has been tracked across 111 weekly CMS publications since Aug 21, 2024.
What are the highest and lowest recorded NADAC prices for VIOKACE 20,880-78,300 UNITS TB?
Since Aug 21, 2024, the NADAC for VIOKACE 20,880-78,300 UNITS TB has ranged from a low of $7.9288 (Nov 20, 2024) to a high of $8.2125 (Sep 30, 2026), with a median of $7.9772 per EA.
Are there cheaper alternatives to VIOKACE 20,880-78,300 UNITS TB?
No other NADAC-published product currently shares the active ingredient and strength of VIOKACE 20,880-78,300 UNITS TB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures VIOKACE 20,880-78,300 UNITS TB?
VIOKACE 20,880-78,300 UNITS TB (NDC 73562020810) is labeled by Aimmune Therapeutics, Inc., and CMS classifies it as a brand product.